Chandler Robinson - 28 Jan 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Executive Officer, Director
Signature
/s/ Quan Vu, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
28 Jan 2025
Net transactions value
$0
Form type
4
Filing time
30 Jan 2026, 14:31:04 UTC
Previous filing
02 Jan 2025
Next filing
07 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Robinson Chandler Chief Executive Officer, Director 1000 SKOKIE BLVD SUITE 350, WILMETTE /s/ Quan Vu, Attorney-in-fact 30 Jan 2026 0001727334

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Other $0 +62,815 $0.000000 62,815 28 Jan 2025 See Footnote F1, F2
holding MNPR Common Stock 85,718 28 Jan 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pro rata liquidating distribution from Tactic Pharma, LLC ("Tactic"), of which the reporting person is a non-controlling member. In prior reports, the reporting person reported beneficial ownership of 272,026 shares of Monopar Therapeutics Inc. common stock held by Tactic.
F2 Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.